{"id":"W4401612362","doi":"10.1016/j.medj.2024.07.022","title":"Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial","year":2024,"lang":"en","type":"article","venue":"Med","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"National Cancer Institute; Genentech; National Institutes of Health; Fondation du cancer des Cèdres; Eisai; MacroGenics; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy; Clovis Oncology; Novocure; Regeneron Pharmaceuticals; National Center for Research Resources; Karyopharm Therapeutics; Merck; GlaxoSmithKline; Amgen; University of Texas MD Anderson Cancer Center; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Ovarian cancer; Oncology; Chemotherapy; Clinical trial; Internal medicine; Cancer; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001334518,0.0007833301,0.001276852,0.0003287111,0.0003130677,0.0008857344,0.0004060986,0.0008296955,0.00257318],"category_scores_gemma":[0.001012403,0.0002478319,0.001092531,0.0003107589,0.0004892372,0.0008162324,0.0002454483,0.002454228,0.0004415313],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007204654,"about_ca_system_score_gemma":0.0007524051,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007432887,"about_ca_topic_score_gemma":0.002441864,"domain_scores_codex":[0.9997213,0.0001273981,0.00001170445,0.000046829,0.00003028613,0.00006247307],"domain_scores_gemma":[0.9996045,0.0001095497,0.00007679245,0.00003182684,0.00003009686,0.0001472821],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6613726,0.02995332,0.004735116,0.001783627,0.003107221,0.0001739791,0.0002470048,0.002371107,0.01523358,0.0004168251,0.005966845,0.2746388],"study_design_scores_gemma":[0.7382503,0.2285933,0.01845269,0.0002282868,0.001850281,0.0002776107,0.0001092412,0.001556644,0.00263492,0.000512961,0.007498201,0.00003564229],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9804845,0.01192579,0.0004943167,0.001286637,0.0002887545,0.001375062,0.001001507,0.00006083926,0.003082603],"genre_scores_gemma":[0.9828517,0.007598917,0.001768622,0.001623733,0.000276743,0.001367933,0.00188938,0.00002183447,0.002601054],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00257318,"threshold_uncertainty_score":0.008608162,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05318943154343298,"score_gpt":0.4073210919774259,"score_spread":0.3541316604339929,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}